Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

"TAS-102: Use at the recommended dose of 35 mg/m² each time, twice a day on the 1st to 5th day and the 8th to 12th day every 28 days, with meals.~Bevacizumab: Once a day on the 1st and 15th day every 28 days, at the recommended dose of 5 mg/kg each time, with meals.~Putlimumab: At the recommended dose of 200 mg/time, intravenous drip, infusion time is 60 minutes, once every 28 days."